Replies to post #74681 on PharmaCyte Biotech Inc (PMCB)

[efood125]

1234....do you think waggs is really running the show? This is gunzburg and salmons technology...they are on the pmcb mgmt team and advisory board...they call the shots...I still think in the end a big pharma will buy out austrianova and pmcb...note that the agreement calls for austrianova not to entertain offers for cell in box or any other of its technologies...why does this agreement mention "any of its other technologies"... what does pmcb have to do with austrianova other technologies yet we got them to agree to this...that is a mistake in my mind that should not have been made public...a smoking gun to me that some big pharma will buyout pmcb and austrianova...for all of its technologies...big money will be involved here...big kaboom coming...that diabetes consortium was told to shutdown letting out any info....it's been a year since we heard anything about diabetes...brandtner was given a grant by Europe to study diabetes...no further info to be found about this...mj info not forthcoming...who is looking at pmcb? Today's news is just the beginning....in my view...also ponder this...this upcoming trial will start soon in my opinion...this deal will be obsolete if the hard stop produces positive results...gunzburg...salmons and waggs work for the same company...it's called cell in box...

[frosr6]

We were a party to the Bavarian Nordic/GSF License Agreement pursuant to which Bavarian Nordic/GSF are the licensors and Bio Blue Bird, our wholly owned subsidiary, is the licensee. The Bavarian Nordic/GSF License Agreement was signed in July 2005 and amended in December 2006 and October 2016. Pursuant to the Bavarian Nordic/GSF License, the licensee is granted an exclusive license to use Bavarian Nordic’s clinical data and know-how encapsulating genetically modified human cells to treat cancer and rights to Bio Blue Bird to the clinical data after expiration of the licensed patent rights. The licensors have rights to terminate the license if the annuity and upkeep fees are not paid to Bavarian Nordic, there is not proper reporting or there is not a clearly documented effort to commercialize this technology. The term of the Bavarian Nordic/GSF License Agreement expired on March 27, 2017, and the parties are currently negotiating an extension.